Brown Miller Wealth Management LLC Purchases 336 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Mar 22nd, 2023

Brown Miller Wealth Management LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,301 shares of the company’s stock after purchasing an additional 336 shares during the period. Johnson & Johnson accounts for about 1.9% of Brown Miller Wealth Management LLC’s holdings, making the stock its 11th biggest position. Brown Miller Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,056,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in shares of Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after buying an additional 3,912,430 shares in the last quarter. FMR LLC increased its position in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after acquiring an additional 3,229,032 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. GQG Partners LLC boosted its position in Johnson & Johnson by 64.4% in the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after purchasing an additional 2,093,392 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

JNJ opened at $153.89 on Wednesday. The firm has a market capitalization of $400.77 billion, a P/E ratio of 22.83, a price-to-earnings-growth ratio of 2.63 and a beta of 0.54. Johnson & Johnson has a one year low of $150.71 and a one year high of $186.69. The company has a fifty day moving average price of $161.11 and a 200-day moving average price of $167.82. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm’s revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.13 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 67.06%.

Insider Buying and Selling at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.35% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Atlantic Securities lifted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a report on Wednesday, January 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 1st. SVB Leerink cut their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a report on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.